Nusinersen Treatment for Older Patients with SMA

SPINRAZA® (nusinersen) Mechanism of Action in Spinal Muscular AtrophyПодробнее

Spinal Muscular Atrophy 2019: Approved Treatment and Upcoming Therapeutic StrategiesПодробнее

Nusinersen Treatment Outcomes in Later Onset SMAПодробнее

Nusinersen (SpinrazaTM): The First FDA Approved Treatment for SMAПодробнее

Nusinersen Treatment for SMAПодробнее

Real-World Experience Treating SMA With NusinersenПодробнее

Nusinersen for Treatment of SMAПодробнее

Treating spinal muscular atrophy in adult patientsПодробнее

Nusinersen in Adults With 5q SMAПодробнее

The Development Journey of Spinraza® (nusinersen): From Advocacy to Treatment and BeyondПодробнее

Nusinersen Treated Type 1 Patients Older Than 7 MonthsПодробнее

Cut and Paste: Treating Spinal Muscular Atrophy with NusinersenПодробнее

Life Saving Spinal Muscular Atrophy (SMA) Treatment | Sam's StoryПодробнее

New Clinical Data on Pediatric Nusinersen treated Patients with SMAПодробнее

Helping Patients With SMA Understand Diagnosis and Treatment in a New Era of TherapyПодробнее

Nusinersen Clinical Trial DataПодробнее

How Spinraza (nusinersen) and Evrysdi treat Spinal Muscular Atrophy (SMA) through splice-switchingПодробнее

Recommended standards of care for adult patients with spinal muscular atrophyПодробнее

Nusinersen: ASO(Anti-Sense- Oligonucleotide) Therapy toward Spinal Muscular Atrophy (SMA) #Code: 198Подробнее